Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Georgia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Georgia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Georgia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Dilawar Khan (NPI 1588725188)

Field	Value
Entity Type	Individual
Organization	Dilawar Khan
Address	255 W 5th St Sw
City	Rome
State	GA
ZIP	30165
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 13, 2006

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

This provider’s Medicare activity is overwhelmingly driven by high-cost infused oncology drugs: J9271 (pembrolizumab) accounts for $1.2M in revenue and 62.3% of the provider’s Medicare revenue, J9299 (nivolumab) accounts for $270.2K and 14.5%, and J0897 (denosumab) accounts for $231.1K and 12.4%. The precomputed top-three concentration is 89.2% of total Medicare revenue, indicating extreme revenue dependence on a small set of injectable oncology agents rather than on office evaluation-and-management or ancillary services.

The code mix (large volumes of J9271, J9299, J0897 alongside chemotherapy administration codes such as 96413, 96417 and infusion add-ons 96411/96415) describes an operational profile of an oncology infusion practice focused on checkpoint inhibitors and supportive bone-protecting biologics. Non-drug E/M and lab codes (for example 99214 with $46.3K, 572 claims and 96413 with $38K, 437 claims) represent a much smaller share of revenue, consistent with a clinic that bills primarily for infused therapeutics rather than high volumes of office visits.

On competitive standing for Medicare drug codes, activity is mixed: J9271 is reported at 27K claims, $43 avg paid/claim, $1.2M revenue and ranks #178 of 1841 providers (90th percentile) and is described in the file as typical, unremarkable volume for this code, while J9299 (11.3K claims, $24 avg, $270.2K) ranks #318 of 505 (37th percentile) and is also described as typical, unremarkable volume. J0897 (12.8K claims, $18 avg, $231.1K) ranks #726 of 10057 (93th percentile) and likewise is labeled as typical, unremarkable volume; overall, the provider appears neither a national outlier dominating multiple product lines nor a low-volume marginal player, but is concentrated in a narrow set of common oncology injectables.

There are a few service-level outliers within the dataset: J2469 (palonosetron) is recorded at 2.3K claims and $2.3K revenue and is explicitly noted as notably above typical national volume, indicating relatively higher antiemetic dispensing compared with peers. Several routine lab and venipuncture codes (for example 36415 with 1.6K claims, $12.5K revenue and a 98th percentile rank) also sit at high national percentiles, suggesting substantial on-site phlebotomy and lab ordering to support infusion workflows.

Payer mix is effectively single-payer: lifetime Medicare revenue is $1.9M while there is no Medicaid billing on file, so the provider relies almost entirely on Medicare reimbursement. This concentration exposes the practice to Medicare policy and fee-schedule changes and means analysts should treat state Medicaid network comparisons as not applicable for this NPI.

Tenure and stability: the NPI was enumerated 2006-12-13 (approximately 20 years ago), indicating long-term enrollment in federal programs and an established billing history; the longevity supports interpretation of the observed code mix as a sustained business model rather than a short-term billing artifact. Analysts should consider this long tenure when assessing referral relationships and continuity of care in the local market.

Operational implication for payers and network managers: because a single drug (J9271) produces the majority of Medicare revenue and the top three codes together represent 89.2% of Medicare receipts, utilization management, contract terms, and specialty pharmacy arrangements focused on checkpoint inhibitors and related infusion services would disproportionately affect this provider’s revenue. Any policy or network changes targeting pembrolizumab use, infusion reimbursement, or site-of-care incentives are therefore likely to have an outsized financial impact on this provider.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

55 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	27,000	$40	$1.2M
J9299	Injection, nivolumab, 1 mg	11,260	$20	$270.2K
J0897	Injection, denosumab, 1 mg	12,840	$20	$231.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	570	$80	$46.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	440	$90	$38K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	220	$70	$15.8K
36415	In this procedure, the provider inserts a needle into a vein to collect a blood sample.	1,560	$10	$12.5K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	1,100	$10	$11K
85025	A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a…	1,470	$10	$10.3K
96417	In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy…	180	$40	$7.6K

Showing 1–10 of 55

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 55 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Georgia Distribution

Dilawar Khan — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Georgia

Full comparison — all codes billed, vs. state median

55 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	40	15,200	$40	$767.3K
J9299	6	10	15,910	$20	$431.3K
J0897	25	290	2,460	$20	$90.2K
J2506	11	10	460	$80	$34.1K
96413	22	160	170	$90	$20.3K
J3490	26	50	50	$320	$19.8K
99214	1,216	13,640	120	$80	$17.8K
J0185	8	20	7,150	$1	$13.9K
82784	5	30	120	$10	$11.1K
96365	112	210	110	$50	$10.8K

Showing 1–10 of 55

Related Providers

Other providers that share a Tax Identification Number (TIN) with Dilawar Khan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dimple Modi	GA	Retina Specialist (Ophthalmology) Physician	$2.7M	$0
Gregory Harris	GA	Hematology & Oncology Physician	$2M	$0
Melissa Dillmon	GA	Hematology & Oncology Physician	$2M	$0
Jeffrey Peller	GA	Rheumatology Physician	$1.1M	$0
Harbin Clinic, LLC	GA	Ambulatory Surgical Clinic/Center	$754.6K	$0
Matthew Mumber	GA	Radiation Oncology Physician	$636.9K	$0
Rahul Garg	GA	Cardiovascular Disease Physician	$605K	$0
John Abdou	GA	Radiation Oncology Physician	$601.9K	$0
Charles Baggett	GA	Cardiovascular Disease Physician	$470.3K	$0
Nzeadibenma Uzochukwu	IL	Diagnostic Radiology Physician	$84K	$360.8K

Nearby Providers

Other providers in the same ZIP code as Dilawar Khan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dr. Miniyars Pediatrics, P.C.	GA	Pediatrics Physician	$0	$18.8M
Floyd Physicians, LLC	GA	Neonatal-Perinatal Medicine Physician	$0	$2.6M
Ear,nose,& Throat Of Northwest Georgia	GA	Otolaryngology Physician	$0	$2M
Amtran Medical Transport Inc	GA	Land Ambulance	$1.8M	$1.7K
Floyd Healthcare Management Inc	GA	Family Medicine Physician	$0	$1.3M
Travis Whitehead	GA	Emergency Medicine Physician	$70.8K	$702.1K
Kathrine Whitehead	GA	Emergency Medicine Physician	$59.8K	$626.1K
Surgery Center Of Rome, LP	GA	Ambulatory Surgical Clinic/Center	$681.8K	$0
Jason Smith	GA	Procedural Dermatology Physician	$445K	$0
Scott Mcdaniel	GA	Professional Counselor	$0	$423.4K

Dilawar Khan — Billing Profile & Reimbursement Data

Sign up for Dilawar Khan — Billing Profile & Reimbursement Data policy alerts

Dilawar Khan — Billing Profile & Reimbursement Data

Sign up for Dilawar Khan — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References